Donald Notman sold $101k of OCUL
Chief Operating Officer at OCULAR THERAPEUTIX, INC. 11,490 shares at an average of $8.82, traded Feb 2, 2026, filed Feb 4, 2026.
Score components
- +20RoleCOO
- +10Trade size$101k at market
- 0Share of holdings soldSold 3.0% of holdings
- +15Cluster4 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +20.1%, 3m +13.6%, 6m -0.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-26-010462, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 2, 2026 | SOpen-market sale Common Stock | -5,455 | $9.14 | $50k | 383,837 | Feb 4, 2026 |
| Feb 4, 2026 | SOpen-market sale Common Stock | -6,035 | $8.54 | $52k | 377,802 | Feb 4, 2026 |
Related signals
Other insiders at OCULAR THERAPEUTIX, INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 11Weak | OCULAR THERAPEUTIX, INC | Jeffrey S. Heier Chief Scientific Officer | $77k 10,869 shares | -3% | |
| 11Weak | OCULAR THERAPEUTIX, INC | Peter Kaiser Chief Development Officer | $70k 9,990 shares | -4% | |
| 35Weak | OCULAR THERAPEUTIX, INC | Donald Notman Chief Operating Officer | $11k 1,099 shares | -0% | |
| 23Weak | OCULAR THERAPEUTIX, INC | Pravin Dugel See Remarks | $233k 21,649 shares | -1% | |
| 16Weak | OCULAR THERAPEUTIX, INC | Jeffrey S. Heier Chief Scientific Officer | $36k 3,296 shares | -1% | |
| 16Weak | OCULAR THERAPEUTIX, INC | Peter Kaiser Chief Development Officer | $33k 3,035 shares | -1% | |
| 10Weak | OCULAR THERAPEUTIX, INC | Sanjay Nayak Chief Strategy Officer | $20k 1,897 shares | -1% | |
| 20Weak | OCULAR THERAPEUTIX, INC | Nadia Waheed Chief Medical Officer | $123k 14,828 shares | -5% | |
| 21Weak | OCULAR THERAPEUTIX, INC | Pravin Dugel See Remarks | $173k 21,156 shares | -1% | |
| 10Weak | OCULAR THERAPEUTIX, INC | Jeffrey S. Heier Chief Scientific Officer | $25k 3,018 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.